Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Davis

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
JMIR Research Protocols|October 1, 2025
Innovative Web-Based Future Planning and Well-Being for Caregivers of Individuals With Intellectual and Developmental Disabilities: Protocol of a Pragmatic Randomized Controlled TrialCaren Steinway, Charmaine Wright, Silvia Kwak, et al.
European Journal of Medicinal Chemistry|October 15, 2022
SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitorRamil Y Baiazitov, Hongyan Qi, Tamil Arasu, et al.
Journal of Applied Research in Intellectual Disabilities : JARID|August 5, 2024
Medicaid long-term services and supports and caregiving needs of caregivers of individuals with intellectual and developmental disabilitiesAriana M Mastrogiannis, Caren Steinway, Telmo C Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancerJohanna Bendell, Mansoor Saleh, April A N Rose, et al.
Journal of Vascular Surgery|August 8, 2006
Protected carotid stenting in high-surgical-risk patients: the ARCHeR resultsWilliam A Gray, L Nelson Hopkins, Sanjay Yadav, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein TranslationMarla Weetall, Thomas Davis, Gary Elfring, et al.
Molecular Cancer Therapeutics|November 22, 2017
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian CancerAnindya Dey, Xunhao Xiong, Aleia Crim, et al.
Journal of Clinical Pharmacology|October 22, 2004
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patientsArshad Ali, Mustafa Hashem, Howard S Rosman, et al.
The Lancet. Neurology|December 21, 2007
Strategies to advance translational research into brain barriersEdward Neuwelt, N Joan Abbott, Lauren Abrey, et al.
International Journal of Cancer|March 12, 2014
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapyMichael Weller, Kerstin Kaulich, Bettina Hentschel, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
JMIR Research Protocols|October 1, 2025
Innovative Web-Based Future Planning and Well-Being for Caregivers of Individuals With Intellectual and Developmental Disabilities: Protocol of a Pragmatic Randomized Controlled TrialCaren Steinway, Charmaine Wright, Silvia Kwak, et al.
European Journal of Medicinal Chemistry|October 15, 2022
SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitorRamil Y Baiazitov, Hongyan Qi, Tamil Arasu, et al.
Journal of Applied Research in Intellectual Disabilities : JARID|August 5, 2024
Medicaid long-term services and supports and caregiving needs of caregivers of individuals with intellectual and developmental disabilitiesAriana M Mastrogiannis, Caren Steinway, Telmo C Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancerJohanna Bendell, Mansoor Saleh, April A N Rose, et al.
Journal of Vascular Surgery|August 8, 2006
Protected carotid stenting in high-surgical-risk patients: the ARCHeR resultsWilliam A Gray, L Nelson Hopkins, Sanjay Yadav, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein TranslationMarla Weetall, Thomas Davis, Gary Elfring, et al.
Molecular Cancer Therapeutics|November 22, 2017
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian CancerAnindya Dey, Xunhao Xiong, Aleia Crim, et al.
Journal of Clinical Pharmacology|October 22, 2004
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patientsArshad Ali, Mustafa Hashem, Howard S Rosman, et al.
The Lancet. Neurology|December 21, 2007
Strategies to advance translational research into brain barriersEdward Neuwelt, N Joan Abbott, Lauren Abrey, et al.
International Journal of Cancer|March 12, 2014
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapyMichael Weller, Kerstin Kaulich, Bettina Hentschel, et al.
Pageof 10